-
Xanomeline (developmental code name LY-246,708;
former proposed brand names Lumeron, Memcor) is a
small molecule muscarinic acetylcholine receptor agonist...
-
Xanomeline/trospium chloride, sold
under the
brand name Cobenfy, is a fixed-dose
combination medication used for the
treatment of schizophrenia. It contains...
- promising. The dual M1, M4
agonist xanomeline has been
proposed as a
potential treatment for schizophrenia.
Xanomeline/trospium
chloride was
approved in...
-
consumption is ****ociated with
weaker symptoms. It
inspired the
development of
xanomeline (see § Drugs below). It
enhances learning and
memory in rodents. AN (Areca...
-
partial agonist.
Xanomeline/trospium
chloride (Cobenfy) - A fixed-dose
combination of
xanomeline and
trospium chloride.
Xanomeline is a functionally...
- long-term
adherence to treatment. The fixed-dose
combination medication xanomeline/trospium
chloride (Cobenfy) was
approved for
medical use in the United...
- ****et, KarXT, an
investigational muscarinic antipsychotic combination of
Xanomeline and Trospium. In
November 2023, the FDA
accepted Karuna Therapeutics'...
-
approved the drug
KarXT (Cobenfy),
which is a
combination drug that
combines xanomeline (a
preferentially acting M1/M4
muscarinic acetylcholine receptor agonist)...
-
Vedaclidine VU-0029767 VU-0090157 VU-0152099 VU-0152100 VU-0238429 WAY-132,983
Xanomeline YM-796
Antagonists 3-Quinuclidinyl
benzilate 4-DAMP
Aclidinium bromide...
-
Vedaclidine VU-0029767 VU-0090157 VU-0152099 VU-0152100 VU-0238429 WAY-132,983
Xanomeline YM-796
Antagonists 3-Quinuclidinyl
benzilate 4-DAMP
Aclidinium bromide...
